Last reviewed · How we verify

NCT05787899

Hypothermia's Effect on Hepatitis B Vaccination

Completed Last updated 28 October 2024
What this trial tests

trial testing Hypothermia Protocol in Hypoxic-Ischemic Encephalopathy in 9 participants. Completed in 1 October 2024.

Timeline
18 May 2023
Primary endpoint
1 October 2024
1 October 2024

Quick facts

Lead sponsorMedical University of South Carolina
StatusCompleted
Study typeOBSERVATIONAL
Enrollment9
Start date18 May 2023
Primary completion1 October 2024
Estimated completion1 October 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of South Carolina

Who can join

Adults 0 Hours to 72 Hours, any sex, with Hypoxic-Ischemic Encephalopathy or Hepatitis B Vaccination. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the research is to determine if the Hepatitis B vaccine after birth provides enough protection after cooling for Hypoxic Ischemic Encephalopathy (HIE). To do this, Hepatitis B titers (blood sample) would be taken before, during, and after administering of the Hepatitis B vaccine series to measure efficacy of the vaccine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypoxic-Ischemic Encephalopathy

Currently open trials in the same condition.

Other Medical University of South Carolina trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05787899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing